Agilent Technologies, Inc. (A) – Resolution Bioscience to enhance the overall product portfolio

The company acquired Resolution Bioscience in Q2FY21 for its strategy of continued investments in
high growth markets. Resolution Bioscience is the key player in key area of cancer diagnostics which will enhance the overall product portfolio of Agilent.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 36